The Egyptian Heart Journal, published by Springer, is a premier open-access journal dedicated to advancing the field of cardiology and cardiovascular medicine. As of 2023, it holds a Q3 classification within the category, showcasing its growing influence within the research community, and ranks 241 out of 387 in Scopus, reflecting a 37th percentile position. With an E-ISSN of 2090-911X, this journal has been open access since 2011, making it easily accessible to researchers, practitioners, and students alike. The journal aims to disseminate high-quality research articles, reviews, and case studies that contribute to the understanding and treatment of cardiovascular diseases. With its focus on innovative and practical solutions in cardiology, the Egyptian Heart Journal plays a critical role in shaping current and future cardiovascular research. Its global outreach and commitment to open access ensure that vital information is available to a wide audience, enhancing both scholarly discourse and clinical practice in the evolving landscape of cardiovascular medicine.

Kidney Diseases is an esteemed open-access journal published by KARGER that has been at the forefront of nephrology research since its inception in 2015. With an impressive Scopus ranking of #13 out of 81 in the field of Medicine Nephrology, placing it in the top 84th percentile, the journal has established itself as a vital resource for researchers, clinicians, and students interested in advancing knowledge on kidney health, disorders, and innovative treatment strategies. This journal aims to disseminate cutting-edge findings and clinical insights over a converged publication span from 2019 to 2024, fostering global collaboration and dialogue within the scientific community. With its commitment to open access, Kidney Diseases ensures that critical research is freely accessible, promoting wider dissemination of knowledge and the development of effective therapeutic interventions.

AKTUELLE RHEUMATOLOGIE is a prominent German journal published by GEORG THIEME VERLAG KG, dedicated to advancing the field of rheumatology. Since its inception in 1978, this peer-reviewed journal has been a vital resource for professionals, researchers, and students engaged in the study and treatment of rheumatic diseases. With an ISSN of 0341-051X and an E-ISSN of 1438-9940, the journal provides a platform for sharing groundbreaking research, clinical studies, and reviews. Although classified in the fourth quartile (Q4) of rheumatology journals and ranked 67 out of 73 in its category according to Scopus, AKTUELLE RHEUMATOLOGIE continues to contribute to the discourse in rheumatology. Its comprehensive coverage of recent advancements and innovative approaches makes it an essential publication for anyone interested in the latest developments in the field.

Clinical Hypertension is a premier journal dedicated to advancing the field of hypertension and cardiovascular health, published by SpringerNature. Since its transition to an Open Access model in 2014, the journal has opened doors for researchers globally to share their findings without barriers, aiming to foster collaboration and innovation in this vital area of medicine. With a current impact factor that positions it in the Q2 quartile for both Cardiology and Cardiovascular Medicine and Internal Medicine, Clinical Hypertension is recognized for its scholarly contributions, reflected in its Scopus rankings (Rank #100/387 in Cardiology and Rank #52/167 in Internal Medicine), which place it in the top percentiles of these competitive fields. Covering a diverse range of topics within hypertension research, it serves as an essential resource for clinicians, researchers, and students alike, promising to keep its audience informed of the latest developments and breakthroughs from its inception in 2017 through to 2024.

Chronic Obstructive Pulmonary Diseases - Journal of the COPD Foundation, published by the esteemed COPD Foundation, serves as a vital platform for advancing research in the field of pulmonary and respiratory medicine. With an ISSN of 2372-952X, this journal emphasizes the exploration and dissemination of knowledge related to chronic obstructive pulmonary disease (COPD) while addressing broader topics in respiratory health. Recognized within the Q2 category of the 2023 *Scopus* rankings and positioned at the 47th percentile in its field, the journal showcases innovative studies, clinical insights, and evidence-based practices crucial for professionals, researchers, and students alike. Although operating as a traditional publication, it seeks to provide immediate access to groundbreaking research on the prevention and management of COPD, facilitating improved patient outcomes. As it continues to expand its influence since its convergence in 2018, this journal is dedicated to bridging gaps in pulmonary medicine, making it an indispensable resource for the global respiratory health community.

The Journal of Asthma and Allergy, published by DOVE MEDICAL PRESS LTD, is a leading open-access journal dedicated to advancing research in the fields of immunology, allergy, and pulmonary medicine. Since its inception in 2008, this journal has provided a vital platform for disseminating high-quality, peer-reviewed research that explores the complexities of asthma and allergy, allowing researchers, professionals, and students to access critical insights without subscription barriers. With an impressive impact factor reflected in its 2023 quartile rankings (Q2) in both Immunology and Allergy, as well as Pulmonary and Respiratory Medicine, the journal stands as a significant contributor to the scientific community, promoting innovative findings that support clinical practice and patient care. Based in New Zealand, the Journal of Asthma and Allergy continues to be at the forefront of research, from its dedication to publishing cutting-edge studies to fostering an inclusive academic discourse that spans the globe. Access to relevant articles is available online, ensuring that all stakeholders in these fields can stay informed and engaged.

HYPERTENSION, published by Lippincott Williams & Wilkins, is a preeminent journal in the field of cardiovascular medicine, focusing on the latest research, therapies, and clinical practices related to hypertension and its associated disorders. With a distinguished Q1 ranking in Internal Medicine and a commendable Scopus rank of #12 out of 167 in its category, it occupies a vital position within the academic community, appealing to researchers, clinicians, and educators alike. The journal has been disseminating impactful findings since 1979 and continues to influence the discourse on hypertension through rigorous peer-reviewed articles, reviews, and studies designed to elevate understanding and treatment of this prevalent condition. HYPERTENSION remains an essential resource for professionals keen on advancing their knowledge in this critical area of medicine, fostering innovations that ultimately improve patient care.

Pulmonary Circulation is a leading open-access journal published by Wiley, focused on advancing the field of pulmonary and respiratory medicine. Established in 2011, the journal has garnered a prestigious reputation, achieving a Q2 ranking in 2023 among its category and ranking #70 out of 155 in Scopus within the specialty of Medicine – Pulmonary and Respiratory Medicine, reflecting its growing influence and relevance in the scientific community. With its commitment to delivering high-quality, peer-reviewed research, Pulmonary Circulation serves as a vital resource for researchers, clinicians, and students seeking to explore innovative ideas and findings in lung health, pulmonary vascular diseases, and therapeutic approaches. The journal has been open access since 2017, ensuring that groundbreaking research is accessible to a wider audience, thus promoting collaboration and knowledge exchange in this dynamic field. Located in the heart of the United States at 111 River St, Hoboken, NJ 07030-5774, the journal is dedicated to fostering advancements in pulmonary health and addressing real-world challenges facing patients globally.

Integrated Blood Pressure Control is a distinguished Open Access journal published by DOVE MEDICAL PRESS LTD in New Zealand, dedicated to advancing the field of cardiology and cardiovascular medicine as well as internal medicine. With its established timeline from 2009 to 2024, this journal has earned a commendable Q2 ranking in both its categories for 2023, reflecting its significant contribution to clinical research and practice. With an ISSN of 1178-7104, it provides a platform for high-quality, peer-reviewed articles that address the complexities of blood pressure management, aiming to improve patient outcomes and foster discussions among healthcare professionals. The journal's open-access model, implemented since 2008, ensures that research findings are readily available to all, promoting greater accessibility and dissemination of knowledge in this critical area of health. Researchers, professionals, and students alike are encouraged to engage with the latest findings and innovative practices published within this journal, which plays an essential role in shaping the future of blood pressure control and related medical fields.

The Journal of Cardiac Failure is a premier peer-reviewed publication dedicated to advancing the understanding and management of heart failure and associated cardiovascular conditions. Published by Churchill Livingstone Inc Medical Publishers, this esteemed journal serves as a vital resource for researchers, clinicians, and healthcare professionals committed to improving patient outcomes in cardiology. With a notable impact factor and ranked in the Q1 category of Cardiology and Cardiovascular Medicine, the journal is recognized for its rigorous scholarly contributions, currently holding a position within the top 15% of its field according to Scopus rankings. The journal spans a comprehensive range of topics, from clinical practices to innovative research in heart failure, fostering knowledge dissemination and collaboration among experts. As it converges from 1994 to 2024, the Journal of Cardiac Failure remains dedicated to publishing high-quality research that shapes the future of cardiovascular medicine, ensuring accessible and impactful scientific dialogue.